Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden

Blood (2025) 146 (Supplement 1): 560.

https://doi.org/10.1182/blood-2025-560

Published: 2025

Journal Articles

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5353.

https://doi.org/10.1182/blood-2025-5353

Published: 2025

Journal Articles

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2025-5352

Published: 2025

Journal Articles

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Blood (2025) 146 (Supplement 1): 5337.

https://doi.org/10.1182/blood-2025-5337

Published: 2025

Journal Articles

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience

Luke Maillie, Stefan Barta, Jordan Carter, Michael Cook, Mitchell Hughes, Daniel Landsburg, Sunita Dwivedy Nasta, Marco Ruella, Stephen Schuster, Jakub Svoboda, Colin Thomas, Emily Tomasulo, Elise Chong

Blood (2025) 146 (Supplement 1): 7119.

https://doi.org/10.1182/blood-2025-7119

Published: 2025

Journal Articles

IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure

Blood (2025) 146 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2025-2394

Published: 2025

Journal Articles

Precision targeting of autoantibody-producing IGHV1-69+ B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP) using chimeric antigen receptor T cells

Ivan Cohen, Roman Khadka, Jean Lemoine, Audrey Bochi-Layec, Seul Jung, Ki Hyun Kim, Huiwu Zhao, Morgan Hresko, Don Siegel, Paolo Ghia, Kostas Stamatopoulos, Stephen Schuster, Vijay Bhoj, Marco Ruella

Blood (2025) 146 (Supplement 1): 426.

https://doi.org/10.1182/blood-2025-426

Published: 2025

Journal Articles

Precision targeting of the malignant clone in B-cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3-23 B cell receptor

Jean Lemoine, Ivan Cohen, Gabrielle Croston, Audrey Bochi-Layec, David Espie, Ranjani Ramasubramanian, Patrizia Porazzi, Federico Stella, Pedram Bayat, Seul Jung, Anastasia Iatrou, Andreas Agathangelidis, Stephen Schuster, Paolo Ghia, Kostas Stamatopoulos, Marco Ruella

Blood (2025) 146 (Supplement 1): 2348.

https://doi.org/10.1182/blood-2025-2348

Published: 2025

Journal Articles

Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies

Zachary Hing, Colin Thomas, Stephen Schuster, Daniel Landsburg, Sunita Dwivedy Nasta, Jakub Svoboda, Jordan Carter, Emeline Chong, Nicole Altomare, Reem Karmali, Venkata Preetam Sandeep Kaduluri, Cole Sterling, Danielle Miller, Zachary Frosch, Stefan Barta

Blood (2025) 146 (Supplement 1): 5409.

https://doi.org/10.1182/blood-2025-5409

Published: 2025

Journal Articles

Deep learning-based image analysis of pretreatment FDG-PET/CT predicts CAR-T cell treatment outcome at month-12 for patients with Relapsed/Refractory large B-cell lymphomas

Stephen Schuster, Yubing Tong, Emeline Chong, Caiyun Wu, Shahbegh Kalra, Sina Dindarian, Drew Torigian, Jayaram Udupa

Blood (2025) 146 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2025-2585

Published: 2025

Journal Articles

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Blood (2025) 146 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2025-1952

Published: 2025

Journal Articles

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Blood (2025) 146 (Supplement 1): 5501.

https://doi.org/10.1182/blood-2025-5501

Published: 2025

Journal Articles

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Emeline Chong, Megan Jones, Guido Ghilardi, Luca Paruzzo, Sunita Dwivedy Nasta, Stefan Barta, Jakub Svoboda, Elise Chong, Jordan Carter, Colin Thomas, Michael Cook, Emily Tomasulo, Marco Ruella, Daniel Landsburg, Stephen Schuster

Blood (2025) 146 (Supplement 1): 3728.

https://doi.org/10.1182/blood-2025-3728

Published: 2025

Journal Articles

Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas

Stefan Barta, Stephen Schuster, Jakub Svoboda, Jordan Carter, Elise Chong, Daniel Landsburg, Sunita Dwivedy Nasta, Ruchi Patel, Joseph Fraietta, Colin Thomas, Omar Elghawy, Ran Reshef, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Siciliano, Rosemary Mazanet, Marco Ruella

Blood (2025) 146 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2025-4174

Published: 2025

Journal Articles

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Blood (2025) 146 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2025-3617

Published: 2025

Journal Articles

Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events

Emily Tomasulo, Emeline Chong, Evani Patel, James Rudolph, Yejin Andrea Kim, Marco Ruella, Alex Watts, Wei-Ting Hwang, Mitchell Hughes, Jakub Svoboda, Daniel Landsburg, Elise Chong, Sunita Dwivedy Nasta, Stefan Barta, Colin Thomas, Michael Cook, Jordan Carter, Michael Fradley, Stephen Schuster

Blood (2025) 146 (Supplement 1): 5680.

https://doi.org/10.1182/blood-2025-5680

Published: 2025

Journal Articles

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Nikita Dave, Imran Nizamuddin, Neha Mehta-Shah, Edd Ricker, Jennifer Amengual, Robert Baiocchi, Timothy Voorhees, Stefan Barta, Jordan Carter, Elise Chong, Michael Cook, Daniel Landsburg, Stephen Schuster, Colin Thomas, Emily Tomasulo, Jakub Svoboda, Sunita Dwivedy Nasta

Blood (2025) 146 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2025-1963

Published: 2025

Journal Articles

Survival outcomes for newly diagnosed non-germinal center large B cell lymphoma patients treated with R-CHOP based on double expressor status and genomic features

Alyssa Klein, Sunita Dwivedy Nasta, Stefan Barta, Jordan Carter, Elise Chong, Jakub Svoboda, Stephen Schuster, Colin Thomas, Emily Tomasulo, Michael Cook, Michael Bowman, Robert Bowman, Daniel Landsburg

Blood (2025) 146 (Supplement 1): 1891.

https://doi.org/10.1182/blood-2025-1891

Published: 2025

Journal Articles

Outcomes in octo- and nonagenarians treated with mogamulizumab-based regimens for cutaneous T-cell lymphoma

Omar Elghawy, Colin Thomas, Daniel Gao, Jordan Carter, Daniel Landsburg, Jakub Svoboda, Elise Chong, Ellen Kim, Alain Rook, Jina Chung, Jennifer Villasenor-Park, Carmela Vittorio, John Plastaras, Michael Lariviere, Harper Hubbeling, Sunita Dwivedy Nasta, Stephen Schuster, Stefan Barta

Blood (2025) 146 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2025-1856

Published: 2025

Journal Articles

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Blood (2025) 146 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2025-4543

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience

IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure

Precision targeting of autoantibody-producing IGHV1-69+ B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP) using chimeric antigen receptor T cells

Precision targeting of the malignant clone in B-cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3-23 B cell receptor

Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies

Deep learning-based image analysis of pretreatment FDG-PET/CT predicts CAR-T cell treatment outcome at month-12 for patients with Relapsed/Refractory large B-cell lymphomas

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Survival outcomes for newly diagnosed non-germinal center large B cell lymphoma patients treated with R-CHOP based on double expressor status and genomic features

Outcomes in octo- and nonagenarians treated with mogamulizumab-based regimens for cutaneous T-cell lymphoma

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only